<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00994877</url>
  </required_header>
  <id_info>
    <org_study_id>34/09</org_study_id>
    <nct_id>NCT00994877</nct_id>
  </id_info>
  <brief_title>Thromboelastography in in Patients With Sepsis</brief_title>
  <official_title>Thromboelastography in Patients Admitted to the ICU for Severe Sepsis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assaf-Harofeh Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assaf-Harofeh Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Methods:&#xD;
&#xD;
      The study is an observational prospective trial that includes 150 patients 18 or older&#xD;
      admitted to our icu because of severe sepsis or septic shock as defined by the American&#xD;
      College of Chest Physicians/ Society of Critical Care Medicine consensus conference.&#xD;
&#xD;
      Patients whose primary reason for hospital admission is sepsis or patients developing sepsis&#xD;
      after elective invasive procedure will be included.&#xD;
&#xD;
      Only patients with known former primary coagulation/hypercoagulability disorder wil be&#xD;
      excluded.&#xD;
&#xD;
      Procedure:&#xD;
&#xD;
      Within 12 hours of admission to the intensive care unit (ICU) blood will be drawn for the&#xD;
      following:&#xD;
&#xD;
      Blood count, glucose, urea, creatinine, liver function tests, prothrombin time, partial&#xD;
      thromboplastin time, Ddimer, fibrinogen and TEG (thromboelastography) assay will be&#xD;
      performed.&#xD;
&#xD;
      These blood tests will be also drawn on day 2 and 4 of admission. On day one, another 3 cc of&#xD;
      blood will be drawn and frozen in -80 degrees for levels of coagulation factors: I, II, V,&#xD;
      VII, VIII, IX, X, XI, XII, XIII, Antithrombin III, protein C, S.&#xD;
&#xD;
      Demographic data will be collected according to patient chart, and the acute physiologic and&#xD;
      chronic health evaluation (APACHE) II score will be assessed after 24 hours. Vital signs will&#xD;
      be collected from monitors.&#xD;
&#xD;
      Informed consent will be waved due to lack of any intervention and the general condition of&#xD;
      patients unable to sign an informed consent.&#xD;
&#xD;
      Control group will include 10 healthy individuals.&#xD;
&#xD;
      End point:&#xD;
&#xD;
      The primary end point is to determine the common hypercoagulable/coagulation disorders&#xD;
      according to TEG.&#xD;
&#xD;
      The secondary end point is to determine whether TEG results have prognostic implications on&#xD;
      this group of severe septic patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2009</start_date>
  <completion_date type="Anticipated">May 2010</completion_date>
  <primary_completion_date type="Anticipated">May 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the common hypercoagulable/ coagulation disorders according to thromboelastography (TEG)</measure>
    <time_frame>In hospital</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine whether TEG results have prognostic implications on this group of severe septic patients</measure>
    <time_frame>28 day</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Shock, Surgical</condition>
  <condition>Systemic Inflammatory Response Syndrome</condition>
  <arm_group>
    <arm_group_label>Septic Patients</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Control</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients With sepsis or septic shock admitted to ICU&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All patients age 18 years or older admitted to ICU whose primary reason for admission&#xD;
             was sepsis or suffering sepsis or septic shock after elective surgical procedure&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients suffering primary disease affecting the coagulation system&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>asaf miller, md</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asaf Harofeh Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ASAF MILLER, MD</last_name>
    <phone>972-577-346002</phone>
    <email>asafmiller@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Asaf Harofeh Medical Center</name>
      <address>
        <city>Beer Yaakov</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>asaf miller</last_name>
      <email>asafmiller@gmail.com</email>
    </contact>
    <investigator>
      <last_name>ASAF MILLER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <reference>
    <citation>Martini WZ, Cortez DS, Dubick MA, Park MS, Holcomb JB. Thrombelastography is better than PT, aPTT, and activated clotting time in detecting clinically relevant clotting abnormalities after hypothermia, hemorrhagic shock and resuscitation in pigs. J Trauma. 2008 Sep;65(3):535-43. doi: 10.1097/TA.0b013e31818379a6.</citation>
    <PMID>18784565</PMID>
  </reference>
  <verification_date>October 2009</verification_date>
  <study_first_submitted>September 24, 2009</study_first_submitted>
  <study_first_submitted_qc>October 13, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 14, 2009</study_first_posted>
  <last_update_submitted>October 13, 2009</last_update_submitted>
  <last_update_submitted_qc>October 13, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 14, 2009</last_update_posted>
  <responsible_party>
    <name_title>ASAF MILLER MD</name_title>
    <organization>Assaf Harofeh Medical Center</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Systemic Inflammatory Response Syndrome</mesh_term>
    <mesh_term>Shock, Surgical</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

